Results for tag: "Blinatumomab"

Blinatumomab is an oncology drug used to treat certain types of cancer, such as acute lymphoblastic leukemia (ALL). It is a monoclonal antibody that works by targeting and killing cancer cells. Blinatumomab is administered intravenously and is approved for use in both adults and children. It is also used in combination with other drugs to treat certain types of lymphoma. Blinatumomab has been shown to be effective in treating ALL, and has been associated with improved overall survival rates in patients with ALL. The Blinatumomab market is a rapidly growing segment of the oncology drug market. It is expected to continue to grow as more patients are diagnosed with ALL and other types of cancer. Blinatumomab is a relatively new drug, and its use is increasing as more clinical trials are conducted and more data is collected. Some companies in the Blinatumomab market include Amgen, Novartis, and Takeda. These companies are involved in the development, manufacturing, and marketing of Blinatumomab. Other companies involved in the market include Celgene, Merck, and Pfizer. Show Less Read more